Protalix BioTherapeutics (PLX) Net Cash Flow (2010 - 2026)

Protalix BioTherapeutics' Net Cash Flow history runs 17 years deep, the most recent figure standing at $26.4 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 9078.91% year-over-year to $26.4 million; the TTM figure through Mar 2026 stood at $21.7 million (up 71.29% YoY), while the FY2025 annual figure was -$5.0 million, down 29.08% from the prior year.
• Net Cash Flow was $26.4 million for Q1 2026 at Protalix BioTherapeutics, up from $1.1 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $26.4 million in Q1 2026 to a low of -$27.8 million in Q3 2023.
• Historically, Net Cash Flow has averaged $1.2 million across 5 years, with a median of -$294000.0 in 2025.
• The sharpest annual moves came in 2022 and 2026: Net Cash Flow plunged 1483.83% in 2022, then jumped 9078.91% in 2026.
• A 5-year view of Net Cash Flow shows it stood at $6.4 million in 2022, then plunged by 49.31% to $3.3 million in 2023, then slumped by 336.8% to -$7.7 million in 2024, then surged by 113.81% to $1.1 million in 2025, then soared by 2381.02% to $26.4 million in 2026.
• The last three Net Cash Flow figures came in at $26.4 million (Q1 2026), $1.1 million (Q4 2025), and -$4.2 million (Q3 2025), per Business Quant data.